Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

Patient derived organoids to model rare prostate cancer phenotypes.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H.

Nat Commun. 2018 Jun 19;9(1):2404. doi: 10.1038/s41467-018-04495-z.

2.

The long tail of oncogenic drivers in prostate cancer.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM; PCF/SU2C International Prostate Cancer Dream Team.

Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z. Epub 2018 Apr 2.

PMID:
29610475
3.

Challenges in validating candidate therapeutic targets in cancer.

Settleman J, Sawyers CL, Hunter T.

Elife. 2018 Feb 8;7. pii: e32402. doi: 10.7554/eLife.32402.

4.

Targeting DNA Repair in Prostate Cancer.

Abida W, Sawyers CL.

J Clin Oncol. 2018 Apr 1;36(10):1017-1019. doi: 10.1200/JCO.2017.76.6592. Epub 2018 Jan 25. No abstract available.

PMID:
29369701
5.

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16.

PMID:
29258679
6.

Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.

Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers CL, Weber WA, Scher HI, Morris MJ, Larson SM.

JAMA Oncol. 2018 Feb 1;4(2):217-224. doi: 10.1001/jamaoncol.2017.3588.

PMID:
29121144
7.

Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis.

Hieronymus H, Iaquinta PJ, Wongvipat J, Gopalan A, Murali R, Mao N, Carver BS, Sawyers CL.

Nat Commun. 2017 Oct 20;8(1):1081. doi: 10.1038/s41467-017-01198-9.

8.

Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.

Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL.

Elife. 2017 Sep 11;6. pii: e27861. doi: 10.7554/eLife.27861.

9.

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.

Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K.

JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137.

PMID:
28873162
10.

Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.

Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI.

JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00029. Epub 2017 May 31.

11.

ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.

Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y; International SU2C/PCF Prostate Cancer Dream Team, Zheng D, Schultz N, Sawyers CL.

Nature. 2017 Jun 29;546(7660):671-675. doi: 10.1038/nature22820. Epub 2017 Jun 14.

12.

Sharing Clinical and Genomic Data on Cancer - The Need for Global Solutions.

Clinical Cancer Genome Task Team of the Global Alliance for Genomics and Health, Lawler M, Haussler D, Siu LL, Haendel MA, McMurry JA, Knoppers BM, Chanock SJ, Calvo F, The BT, Walia G, Banks I, Yu PP, Staudt LM, Sawyers CL.

N Engl J Med. 2017 May 25;376(21):2006-2009. doi: 10.1056/NEJMp1612254. No abstract available.

13.

Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape.

Vis DJ, Lewin J, Liao RG, Mao M, Andre F, Ward RL, Calvo F, Teh BT, Camargo AA, Knoppers BM, Sawyers CL, Wessels LFA, Lawler M, Siu LL, Voest E; Clinical Working Group of the Global Alliance for Genomics and Health.

Ann Oncol. 2017 May 1;28(5):1145-1151. doi: 10.1093/annonc/mdx037.

14.

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL.

Science. 2017 Jan 6;355(6320):84-88. doi: 10.1126/science.aah4307.

15.

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.

Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers CL, Ellis L, Goodrich DW.

Science. 2017 Jan 6;355(6320):78-83. doi: 10.1126/science.aah4199.

16.

Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome.

Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, Zhang L, Huang K, Stoyanova T, Park JW, Shkhyan RO, Nowroozizadeh B, Rettig MB, Sawyers CL, Elashoff D, Horvath S, Huang J, Witte ON, Goldstein AS.

Cell Rep. 2016 Dec 6;17(10):2596-2606. doi: 10.1016/j.celrep.2016.11.010.

17.

A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon.

Gao D, Zhan Y, Di W, Moore AR, Sher JJ, Guan Y, Wang S, Zhang Z, Murphy DA, Sawyers CL, Chi P, Chen Y.

PLoS One. 2016 Aug 18;11(8):e0161084. doi: 10.1371/journal.pone.0161084. eCollection 2016.

18.

Facilitating a culture of responsible and effective sharing of cancer genome data.

Siu LL, Lawler M, Haussler D, Knoppers BM, Lewin J, Vis DJ, Liao RG, Andre F, Banks I, Barrett JC, Caldas C, Camargo AA, Fitzgerald RC, Mao M, Mattison JE, Pao W, Sellers WR, Sullivan P, Teh BT, Ward RL, ZenKlusen JC, Sawyers CL, Voest EE.

Nat Med. 2016 May 5;22(5):464-71. doi: 10.1038/nm.4089.

19.

Organoid culture systems for prostate epithelial and cancer tissue.

Drost J, Karthaus WR, Gao D, Driehuis E, Sawyers CL, Chen Y, Clevers H.

Nat Protoc. 2016 Feb;11(2):347-58. doi: 10.1038/nprot.2016.006. Epub 2016 Jan 21.

20.

Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins.

Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers CL, Lewis JS, Evans MJ.

Mol Pharm. 2016 Feb 1;13(2):683-8. doi: 10.1021/acs.molpharmaceut.5b00882. Epub 2016 Jan 12.

21.

Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors.

Agarwal S, Hynes PG, Tillman HS, Lake R, Abou-Kheir WG, Fang L, Casey OM, Ameri AH, Martin PL, Yin JJ, Iaquinta PJ, Karthaus WR, Clevers HC, Sawyers CL, Kelly K.

Cell Rep. 2015 Dec 15;13(10):2147-58. doi: 10.1016/j.celrep.2015.10.077. Epub 2015 Nov 25.

22.

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.

Watson PA, Arora VK, Sawyers CL.

Nat Rev Cancer. 2015 Dec;15(12):701-11. doi: 10.1038/nrc4016. Epub 2015 Nov 13. Review.

23.

All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health.

Lawler M, Siu LL, Rehm HL, Chanock SJ, Alterovitz G, Burn J, Calvo F, Lacombe D, Teh BT, North KN, Sawyers CL; Clinical Working Group of the Global Alliance for Genomics and Health (GA4GH).

Cancer Discov. 2015 Nov;5(11):1133-6. doi: 10.1158/2159-8290.CD-15-0821.

24.

Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.

Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL.

Cancer Res. 2015 Nov 15;75(22):4688-96. doi: 10.1158/0008-5472.CAN-15-0892. Epub 2015 Oct 2.

25.

Identification of an oncogenic RAB protein.

Wheeler DB, Zoncu R, Root DE, Sabatini DM, Sawyers CL.

Science. 2015 Oct 9;350(6257):211-7. doi: 10.1126/science.aaa4903. Epub 2015 Sep 3.

26.

Integrative Clinical Genomics of Advanced Prostate Cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Sboner A, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 Jul 16;162(2):454. doi: 10.1016/j.cell.2015.06.053. Epub 2015 Jul 16. No abstract available.

27.

Integrative clinical genomics of advanced prostate cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 May 21;161(5):1215-1228. doi: 10.1016/j.cell.2015.05.001. Erratum in: Cell. 2015 Jul 16;162(2):454.

28.

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N.

Cancer Cell. 2015 Jan 12;27(1):109-22. doi: 10.1016/j.ccell.2014.11.008. Epub 2014 Dec 24.

29.

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling.

Wanjala J, Taylor BS, Chapinski C, Hieronymus H, Wongvipat J, Chen Y, Nanjangud GJ, Schultz N, Xie Y, Liu S, Lu W, Yang Q, Sander C, Chen Z, Sawyers CL, Carver BS.

Mol Cancer Ther. 2015 Jan;14(1):278-88. doi: 10.1158/1535-7163.MCT-14-0542-T. Epub 2014 Nov 7.

30.

MAGI-2 scaffold protein is critical for kidney barrier function.

Balbas MD, Burgess MR, Murali R, Wongvipat J, Skaggs BJ, Mundel P, Weins A, Sawyers CL.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14876-81. doi: 10.1073/pnas.1417297111. Epub 2014 Sep 30.

31.

Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.

Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00026.

32.

Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: a policy statement from the american association for cancer research.

Sawyers CL, van 't Veer LJ.

Clin Cancer Res. 2014 Oct 1;20(19):4978-81. doi: 10.1158/1078-0432.CCR-14-2295. Epub 2014 Sep 9. No abstract available.

33.

Organoid cultures derived from patients with advanced prostate cancer.

Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers CL, Chen Y.

Cell. 2014 Sep 25;159(1):176-187. doi: 10.1016/j.cell.2014.08.016. Epub 2014 Sep 4.

34.

Identification of multipotent luminal progenitor cells in human prostate organoid cultures.

Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, Vries RGJ, Cuppen E, Chen Y, Sawyers CL, Clevers HC.

Cell. 2014 Sep 25;159(1):163-175. doi: 10.1016/j.cell.2014.08.017. Epub 2014 Sep 4.

35.

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.

Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW.

Genes Dev. 2014 Aug 15;28(16):1800-14. doi: 10.1101/gad.244368.114.

36.

Copy number alteration burden predicts prostate cancer relapse.

Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, Heguy A, Huberman K, Bernstein M, Assel M, Murali R, Vickers A, Scardino PT, Sander C, Reuter V, Taylor BS, Sawyers CL.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11139-44. doi: 10.1073/pnas.1411446111. Epub 2014 Jul 14.

37.

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.

Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL.

Cell. 2013 Dec 5;155(6):1309-22. doi: 10.1016/j.cell.2013.11.012.

38.

"N of 1" case reports in the era of whole-genome sequencing.

Brannon AR, Sawyers CL.

J Clin Invest. 2013 Nov;123(11):4568-70. doi: 10.1172/JCI70935. Epub 2013 Oct 25.

39.

AACR Cancer Progress Report 2013.

AACR Cancer Progress Report Writing Committee, Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, Foti M, Jemal A, Lawrence TS, Li CI, Mardis ER, Neumann PJ, Pardoll DM, Prendergast GC, Reed JC, Weiner GJ.

Clin Cancer Res. 2013 Oct 15;19(20 Suppl):S4-98. doi: 10.1158/1078-0432.CCR-13-2107. Epub 2013 Sep 16. No abstract available.

40.

Androgen receptor signaling regulates DNA repair in prostate cancers.

Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D, Carver BS, Chen Y, Watson PA, Shah NP, Fujisawa S, Goglia AG, Gopalan A, Hieronymus H, Wongvipat J, Scardino PT, Zelefsky MJ, Jasin M, Chaudhuri J, Powell SN, Sawyers CL.

Cancer Discov. 2013 Nov;3(11):1245-53. doi: 10.1158/2159-8290.CD-13-0172. Epub 2013 Sep 11.

41.

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, Larson SM, Sawyers CL, Scher HI.

J Clin Oncol. 2013 Oct 1;31(28):3525-30. doi: 10.1200/JCO.2013.50.1684. Epub 2013 Sep 3.

42.

ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.

Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J, Scher HI, Zheng D, Sawyers CL.

Nat Med. 2013 Aug;19(8):1023-9. doi: 10.1038/nm.3216. Epub 2013 Jun 30.

43.

Perspective: combined forces.

Sawyers CL.

Nature. 2013 Jun 27;498(7455):S7. doi: 10.1038/498S7a. No abstract available.

PMID:
23803949
44.

Developing standards for breakthrough therapy designation in oncology.

Horning SJ, Haber DA, Selig WK, Ivy SP, Roberts SA, Allen JD, Sigal EV, Sawyers CL.

Clin Cancer Res. 2013 Aug 15;19(16):4297-304. doi: 10.1158/1078-0432.CCR-13-0523. Epub 2013 May 29.

45.

Overcoming mutation-based resistance to antiandrogens with rational drug design.

Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL.

Elife. 2013 Apr 9;2:e00499. doi: 10.7554/eLife.00499.

46.

β4 Integrin signaling induces expansion of prostate tumor progenitors.

Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL, Giancotti FG.

J Clin Invest. 2013 Feb;123(2):682-99. doi: 10.1172/JCI60720. Epub 2013 Jan 25.

47.

The 2011 Gordon Wilson Lecture: overcoming resistance to targeted cancer drugs.

Sawyers CL.

Trans Am Clin Climatol Assoc. 2012;123:114-23; discussion 123-5.

48.

Imaging tumor burden in the brain with 89Zr-transferrin.

Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers CL, Lewis JS.

J Nucl Med. 2013 Jan;54(1):90-5. doi: 10.2967/jnumed.112.109777. Epub 2012 Dec 12.

49.

Cancer drug development. Preface.

Sawyers CL, Mellinghoff IK.

Curr Top Microbiol Immunol. 2012;355:v-vi. No abstract available.

PMID:
23227490
50.

Annotating MYC status with 89Zr-transferrin imaging.

Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS.

Nat Med. 2012 Oct;18(10):1586-91. doi: 10.1038/nm.2935. Epub 2012 Sep 23.

Supplemental Content

Loading ...
Support Center